

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
Army 111A/118

In Re Application Of: Jeyanthi

JUN 16 2005

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/337,945	June 22, 1999	Tran	30951	1615	9742

Title: Novel "Burst-Free" Sustained Release....

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 Army 111A/118

In Re Application: Jeyanthi

JUN 16 2005



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/337,945	June 22, 1999	Tran	30951	1615	9742

Title: Novel "Burst-Free" Sustained Release....

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

 (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

 June 14, 2005
 (Date)

 Caroline Nash
 Signature of Person Mailing Correspondence

 Caroline Nash

 Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

 Caroline Nash
 Signature

Dated:

 June 14, 2005

CC:

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUN 16 2005

Docket Number (Optional)

Army 11A/118

Application Number

09/337,945

Applicant(s)

Teyanthi, et al

Filing Date

02/22/99

Group Art Unit

1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3,540,444	11/17/70	Moreland	128	173	1/15/68
	BB	3,788,315	1/29/74	Laurens	128	173H	4/20/71
	CC	4,166,800	9/4/79	Fong	252	316	7/31/78
	DD	4,384,975	5/24/83	Fong	427	213.36	6/13/80
	EE	4,530,840	7/23/85	Tice et al.	514	179	7/29/82
	FF	4,542,025	9/17/85	Tice et al.	424	78	4/30/84
	GG	4,622,244	11/11/86	Lapka et al.	427	213.32	8/23/84
	HH	4,585,482	4/29/86	Tice et al.	106	15.05	5/25/84
	II	4,637,905	1/20/87	Gardner	264	4.3	4/11/85
	JJ	4,675,189	6/23/87	Kent et al.	424	490	2/8/85
	KK	4,798,786	1/17/89	Tice et al.	435	177	5/6/82

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
ab	0052510B2	10/19/94	EPO	A61K	9/50	✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

aa	Gilding, Biodegradable polymers for use in surgery-polyglycolic/poly (ac c acid) homo- and copolymers: 1, Polymer, vol. 20, Dec. 1979, pp1459-1464
bb	Biotechnology News, August 22, 1997, vol. 17, No. 20, Topical DNA vaccine elicits immune response.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

A circular postmark from the U.S. Patent and Trademark Office, Washington, DC. The outer ring contains the text "U.S. PATENT & TRADEMARK OFFICE" at the top and "WASH. D.C." at the bottom. The inner circle contains "O I P E" at the top, "JUN 16 2005" in the center, and "CLOSURE CITATION" at the bottom. A small "S" is visible at the very bottom right.

Docket Number (Optional) Army	Application Number
Applicant(s) Sgt. John Doe	
Filing Date	Group Art Unit

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LL	4,798,786	1/17/89	Tice et al.	435	177	5/6/82
	MM	4,835,139	5/30/89	Tice et al.	514	15	5/19/87
	NN	4,863,735	9/5/89	Kohn et al.	524	422	10/2/86
	OO	4,897,268	1/30/90	Tice et al.	424	422	8/3/87
	PP	4,938,763	7/3/90	Dunn et al.	604	891.1	10/3/88
	QQ	4/941/880	7/17/90	Burns	604	143	12/12/88
	RR	5,000,886	3/19/91	Lawter et al.	264	4.3	5/26/87
	SS	5,019,096	5/28/91	Fox, Jr. et al.	623	1	10/14/88
	TT	5,059,187	10/22/91	Sperry et al.	604	290	5/4/90
	UU	5,064,413	11/12/91	McKinnon et al.	604	70	11/9/89
	VV	5,075,109	12/24/91	Tice et al.	424	88	3/18/88

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	cc	Hall, et al., Purification and Analysis of Colonization Factor Antigen I, Coli Surface Antigen 1, and Coli Surface ANtigen 3 Fimbriae from Enterotoxigenic Escherichia Coli, Journal of Bacteriology, Nov. 1989, p6372-6374, vol. 171, No. 11
	dd	Evans, et al. Purification and Characterization of the CFR/I Antigen of Enterotoxigenic Escherichia coli, Infection and Immunity, Aug. 1979, p 738-748, vol. 25.

EXAMINER _____ **DATE CONSIDERED** _____

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUN 16 2005

Docket Number (Optional)

Army

Application Number

Applicant(s)

Filing Date

Group Art Unit

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	VV	5,075,109	12/24/91	Tice, et al.	424	88	3/18/88
	WW	5,102,872	4/7/92	Singh, et al.	514	21	8/12/88
	XX	5,129,825	7/14/92	Discko, Jr.	433	90	10/10/89
	YY	5,133,701	7/28/92	Han	604	289	10/15/90
	ZZ	5,236,355	8/17/93	Brizzolara et al.	433	80	10/5/90
	AB	5,278,202	1/11/94	Dunn et al.	523	113	12/23/91
	AC	5,290,494	3/1/94	Coombes et al.	264	41	7/16/92
	AD	5,360,610	11/1/94	Tice et al.	424	426	3/15/93
	AE	5,384,133	1/24/95	Boyes, et al.	424	501	6/29/93
	AF	5,407,609	4/18/95	Tice et al.	264	46	5/17/93
	AG	5,417,986	5/23/95	Reid et al.	424	499	4/10/92

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ee	Karjalainen, et al., Molecular Cloning and Nucleotide Sequence of the Colonization Factor Antigen I Gene of Escherichia coli, Infection and Immunity, Apr. 1989, p1126-1130, vol. 57
ff	Jeyanthi, et al., Novel, Burst Free Programmable Biodegradable Microspheres For Controlled Release of Polypeptides, Proceedings Int. Symp. control Release Bioact. Mater. (1996) p351-352/

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUN 16 2008

RECEIVED
U.S. PATENT & TRADEMARK OFFICE

Docket Number (Optional) Application Number

Army

Applicant(s)

Filing Date

Group Art Unit

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AH	5,500,228	3/19/96	Lawter et al.	424	486	11/26/90
	AI	5,538,739	7/23/96	Bodmer et al.	424	501	1/18/91
	AJ	5,639,480	6/17/97	Bodmer et al.	424	501	6/6/95
	AK	5,643,605	7/1/97	Cleland et al.	424	489	6/2/95
	AL	5,688,530	11/18/97	Bodmer, et al.	424	501	6/6/95
	AM	5,693,343	12/2/97	Reid, et al.	424	491	5/16/94
	AN	5,762,965	6/9/98	Burnett et al.	424	499	2/9/96
	AP	5,811,128	9/22/98	Tice, et al.	424	501	9/7/93
	AQ	5,814,344	9/29/98	Tice, et al.	424	501	6/6/95
	AR	5,820,883	10/13/98	Tice, et al.	424	501	6/6/95
	AS	5/853,763	12/29/98	Tice, et al.	424	489	6/6/95

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

gg	Yeh, A novel emulsification-solvent extraction technique for production of protein loaded biodegradable microparticles for vaccine and drug delivery, Journal of Controlled Release, 33 (1005) 437-445.
hh	Yan, Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by water-in-oil-in-water emulsion technique, Journal of Controlled Release, 32 (1994) 231-241.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-A820
(also form PTO-1449)

P09A/REV04


Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

SHEET 5 OF 7

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUN 16 2005



Docket Number (Optional)

Army

Application Number

Applicant(s)

Filing Date

Group Art Unit

*EXAMINER
INITIAL

PERTINENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

gg	Wang, et al., Influence of formulation methods on the in vitro controlled release of protein from poly (ester) microspheres Journal of Controlled Release, 17 (1991) 23-32.
hh	Brown, Wonder Drugs' Losing Healing Aura, The Washington Post, June 26, 1995, A section.
ii	Setterstrom, Controlled Release of Antibiotics From biodegradable Microcapsules For Wound infection Control, Chemical Abstracts, 1983, pp215-226.
jj	Perez-Casal, et al., Gene Encoding the Major Subunit of CS1 Pili of Human Enterotoxigenic Escherichia Coli, Infection and Immunity, Nov., 1990, p 3594-3600, vol. 58, No. 11.
kk	Jordi, et al., Analysis of the first two genes of the CS1 fimbrial operon in human enterotoxigenic Escherichia coli of serotype 0139: H28, FEMS Microbiology Letters 80, (1991) p265-270.
ll	Tan, et al., Mapping the Antigenic Epitopes of Human Dihydrofolate Reductase by Systematic Synthesis of Peptides on solid Supports, The Journal of Biological Chemistry, vol. 265, No. 14, Issue of May 15, pp. 8022-8026 (1990)
mm	McConnel, et al., Antigenic homology within human enterotoxigenic Esherichia coli fimbrial colonization factor antigens: CFA/I, coli-surface-associated antigens (CS)1, CS2, CS4 and CS17, FEMS Microbiology Letters 61 (1989) 105-108.
nn	Van der Zee, Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides, Eur. J. Immunol. 1989, 19: 43-47.
oo	Cassels, et al., Analysis of Escherichia coli Colonization Factor Antigen I Linear B-Cell Epitopes, as Determined by Primate Responses, following Protein Sequence Verification, Infection and Immunity, June 1992, p. 2174-2181, vol. 60, no. 6.
pp	Romagnoli, et al. Peptide-MHC Interaction: A Rational Approach to Vaccine Design, Inter, RE. Immunol. 6, 1990, 00 61-73.
qq	Maister, First Oral AIDS Vaccine Trials Near, BioWorld Today, Tuesday, April 19, 1994, p.4.
rr	Rognan, et al., Molecular Modeling of an Antigenic Complex Between a Viral Peptide and a Class I Major Histocompatibility Glycoprotein, Proteins Structure, Function and Genetics 13 70-85 (1992).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

Army

Application Number

Applicant(s)

Filing Date

Group Art Unit

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ss

Brown, A hypothetical model of the foreign antigen blinding site of Class II histocompatibility molecules, Nature, vol. 332, 28 April 1988, p845-850.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.